Related Experiment Video
Updated: Jun 1, 2026
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
[Hyperuricemia in chronic heart failure].
Kardiologiia
|June 2, 2011
Summary
High uric acid levels (hyperuricemia) are common in chronic heart failure (CHF) and indicate oxidative stress, negatively impacting heart function and patient outcomes.
Area of Science:
- Cardiology
- Nephrology
- Metabolic Disorders
Context:
- Hyperuricemia is linked to obesity, insulin resistance, metabolic syndrome, diuretic use, aging, and impaired kidney function.
- Elevated uric acid levels correlate with hypertension, diabetes, ischemic heart disease, and chronic heart failure (CHF).
- Approximately 60% of patients hospitalized for CHF decompensation exhibit hyperuricemia.
Purpose:
- To explore the role of isolated hyperuricemia in chronic heart failure (CHF).
- To identify hyperuricemia as a marker of oxidative stress in CHF patients.
- To understand the negative impact of hyperuricemia on the cardiovascular system in CHF.
Summary:
- Isolated hyperuricemia in CHF, independent of renal function or medication, signifies altered oxidative metabolism.
- It is characterized by increased free radicals that damage heart muscle cells and blood vessel linings.
- This damage leads to reduced heart contractility and blood vessel constriction.
Impact:
- Hyperuricemia, alongside insulin resistance, hypoxia, and inflammation, exacerbates cardiovascular issues in CHF.
- It is associated with a poorer prognosis for patients suffering from chronic heart failure.
- Managing hyperuricemia may be crucial for improving cardiovascular health and outcomes in CHF patients.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...